Cargando…
Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
In order to develop original water soluble antagonists of X‐linked inhibitor of apoptosis protein (XIAP), a novel bicyclic scaffold was designed based on 8,5‐fused bicyclic lactam. During its preparation, a spontaneous rearrangement from 8,5‐ to 7,5‐fused bicyclic lactam was observed and confirmed b...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331714/ https://www.ncbi.nlm.nih.gov/pubmed/30652062 http://dx.doi.org/10.1002/open.201800260 |
_version_ | 1783387188344389632 |
---|---|
author | Sheng, Zhaojun J. Shi, Yiming M. Xu, Ximing Bellynck, Sébastien Zhang, Kun Du, Zhiyun Y. Xu, Xuetao Maurel, François Dong, Chang‐Zhi |
author_facet | Sheng, Zhaojun J. Shi, Yiming M. Xu, Ximing Bellynck, Sébastien Zhang, Kun Du, Zhiyun Y. Xu, Xuetao Maurel, François Dong, Chang‐Zhi |
author_sort | Sheng, Zhaojun J. |
collection | PubMed |
description | In order to develop original water soluble antagonists of X‐linked inhibitor of apoptosis protein (XIAP), a novel bicyclic scaffold was designed based on 8,5‐fused bicyclic lactam. During its preparation, a spontaneous rearrangement from 8,5‐ to 7,5‐fused bicyclic lactam was observed and confirmed by MS and NMR analyses, in particular the HMBC spectra. DFT calculations were performed to understand the corresponding mechanism. It was finally prevented through changing the reaction order in the synthesis route and a Smac mimetic with this core structure, ZJ‐1 was successfully obtained. The structure of this new bicyclic scaffold was well confirmed by HRMS and NMR ((1)H, (13)C, NOESY) analyses. ZJ‐1 presented in addition a binding affinity to XIAP‐BIR3, nearly 6 times better than that of AVPI, similar to the reported SM‐128 in an in vitro fluorescence polarization (FP) assay. This preliminary result suggests that this new bicyclic scaffold could be very attractive in the development of novel anticancer agents targeting XIAP. |
format | Online Article Text |
id | pubmed-6331714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63317142019-01-16 Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams Sheng, Zhaojun J. Shi, Yiming M. Xu, Ximing Bellynck, Sébastien Zhang, Kun Du, Zhiyun Y. Xu, Xuetao Maurel, François Dong, Chang‐Zhi ChemistryOpen Full Papers In order to develop original water soluble antagonists of X‐linked inhibitor of apoptosis protein (XIAP), a novel bicyclic scaffold was designed based on 8,5‐fused bicyclic lactam. During its preparation, a spontaneous rearrangement from 8,5‐ to 7,5‐fused bicyclic lactam was observed and confirmed by MS and NMR analyses, in particular the HMBC spectra. DFT calculations were performed to understand the corresponding mechanism. It was finally prevented through changing the reaction order in the synthesis route and a Smac mimetic with this core structure, ZJ‐1 was successfully obtained. The structure of this new bicyclic scaffold was well confirmed by HRMS and NMR ((1)H, (13)C, NOESY) analyses. ZJ‐1 presented in addition a binding affinity to XIAP‐BIR3, nearly 6 times better than that of AVPI, similar to the reported SM‐128 in an in vitro fluorescence polarization (FP) assay. This preliminary result suggests that this new bicyclic scaffold could be very attractive in the development of novel anticancer agents targeting XIAP. John Wiley and Sons Inc. 2019-01-15 /pmc/articles/PMC6331714/ /pubmed/30652062 http://dx.doi.org/10.1002/open.201800260 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Full Papers Sheng, Zhaojun J. Shi, Yiming M. Xu, Ximing Bellynck, Sébastien Zhang, Kun Du, Zhiyun Y. Xu, Xuetao Maurel, François Dong, Chang‐Zhi Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams |
title | Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
|
title_full | Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
|
title_fullStr | Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
|
title_full_unstemmed | Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
|
title_short | Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
|
title_sort | development of xiap antagonists based on de novo 8,5‐fused bicyclic lactams |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331714/ https://www.ncbi.nlm.nih.gov/pubmed/30652062 http://dx.doi.org/10.1002/open.201800260 |
work_keys_str_mv | AT shengzhaojunj developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT shiyimingm developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT xuximing developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT bellyncksebastien developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT zhangkun developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT duzhiyuny developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT xuxuetao developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT maurelfrancois developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams AT dongchangzhi developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams |